Sanofi’s Triomphe On Vaccine Plants Of The Future, Regulatory Speed
Singapore Deputy PM stresses preparation for next pandemic
Executive Summary
Sanofi's executive vice-president and head of vaccines, Thomas Triomphe, outlines in an interview with Scrip the role of evolutive vaccine facilities that are adaptable to new platforms like mRNA, a core cog expected to drive the French group’s innovation ambitions. Finding a sustainable ‘sweet spot’ when it comes to regulatory speed post the pandemic is among the other topics the executive touched upon.
You may also be interested in...
GSK CTO, Boehringer Exec On The Metaverse And Pharma’s Foot In The Door
Big pharma executives discuss the transformative potential of the metaverse in the life sciences segment and how things are shaping in the virtual world amid the hype. GSK’s senior VP and chief technology officer outlines to Scrip gains made deploying digital twins and bots.
Singapore Govt Links With GSK, Takeda, Sanofi In Biopharma Manufacturing Boost
As Singapore aims for growth in its biopharma manufacturing capability, three key players in the pharmaceutical industry announced plans to join a newly-formed public-private consortium designed to foster innovation in the production of vaccines and biologics.
Merck KGaA Exec On Gearing For mRNA Prime Time, De-Risking Manufacturing
Benoit Opsomer, vice-president and head of bioprocessing, Asia Pacific, Merck Life Science, explains how recent targeted CDMO buyouts put the German group in pole position with services across the mRNA value chain, even as it supports global players such as BioNTech. Striking multi-country expansion of manufacturing footprint, including in China, is also underway amid rising demand for biopharma single-use assemblies.